Navigation Links
Next-generation allergy vaccines to be developed in Finland to create effective and safe desensitization therapies
Date:10/21/2011

VTT holds patents on gene technology which can be applied to alter the structure of an allergen, i.e. a protein causing allergy, so that it will cause less allergic symptoms than the original allergen, while remaining effective in desensitisation therapy.

"The vaccine helps to improve the protection to the allergen, thus, alleviating the symptoms. That's why we prefer to use the term vaccine, instead of medication," VTT's Senior Advisor Hans Sderlund explains. The research objective is to develop an orally administered vaccine.

The foundation for this development rests on a scientific breakthrough dating back five years to a co-operation project involving VTT, the University of Eastern Finland and HUCH Skin and Allergy Hospital. Researchers were able to determine how an IgE antibody binds an allergen and were the first to present a detailed 3D structure of this complex. This proved to be different from what scientists around the world had anticipated.

Initially, Desentum Oy will develop a product line of 20 to 25 new hypoallergens which could be used as vaccines for some of the most important allergies. These include pollens (birch, hay, common wormwood, etc.), allergens from pets, and proteins associated with food allergies (fish, nuts, apple, celery). Clinical testing of the first products is anticipated to start within the next three years.

Pekka Mattila, Desentum Oy's Managing Director, knows how to run a biotechnology company and increase its business opportunities. He was one of the founding members of the Finnzymes Group and acted as its CEO until 2010, when the company was sold to the American Thermo Fisher Scientific.

What is an allergy?

Allergies are caused by the immune reaction to normally harmless proteins allergens - present in environment, food or consumer and medical products. Due to sensitisation, the body generates Immunoglobulin E (IgE) antibodies. Next time when these antibodies recognise the same allergen, they trigger an allergic reaction and cause symptoms in the respiratory or digestive system, or the skin. An extreme allergic reaction may cause anaphylaxis or even death.

The prevalence of allergies and allergic reactions has increased in the industrialised countries, and they are now estimated to belong to the top five most costly disease groups. In Europe, the number of people suffering from allergies is estimated to exceed 80 million, while in the US the corresponding number is 65 million. According to further estimates, half of the European population will suffer from an allergy by 2015.

In the US alone, the market for antiallergic drugs is anticipated to exceed USD 15 billion by 2015. In 2010, the estimated market for new allergy vaccines is approximately USD 700 million.


'/>"/>

Contact: Hans Soderlund Professor
Hans.soderlund@vtt.fi
358-207-225-104
VTT Technical Research Centre of Finland
Source:Eurekalert

Related medicine news :

1. In search of cancers common ground: A next-generation view
2. Next-generation hospital design can improve health -- and save money
3. Proteins in unroasted coffee beans may become next-generation insecticides
4. Viscira™ Earns Industry Praise for Next-Generation 3D Animation Production
5. Pharmacokinetic/Pharmacodynamic Data Support Further Development of Tobiras Next-Generation CCR5 Receptor Antagonist
6. Black Children May Be More Prone to Peanut Allergy, Study Finds
7. Switch to Powder-Free Latex Gloves Cuts Health Workers Allergy Risk
8. Longer Allergy Season Means More Misery
9. Using powder-free latex gloves reduces latex allergy rate in health care workers
10. Nut-allergy sufferers face prejudice -- new study
11. Prenatal pet exposure, delivery mode, race are key factors in early allergy risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... 2016 , ... Diagnotes, a leader in digital healthcare communications, ... system in South Carolina, to provide its secure mobile communication platform. , “Healthcare ... drives workflow efficiencies and improves provider and patient satisfaction,” said Dr. Todd Rowland, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Each year, about 800,000 people suffer from cerebral ... United States and account for one death every four minutes. Many people who ... HCR ManorCare is launching a video series called “Your Brain,” in conjunction with its ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... industry, announced today that Legacy Health is expanding its use of Intrigma’s cloud-based ... a highly successful initial proof of concept. The Portland, Oregon based health system ...
(Date:5/3/2016)... ... 03, 2016 , ... Huntington Beach orthopedic doctor , Dr. Rick Pospisil, ... be used to diagnose and treat joint problems. During this procedure, Dr. Pospisil makes ... special lighting system and lens that illuminate and magnify the various structures in the ...
(Date:5/3/2016)... ... May 03, 2016 , ... Finding the right way to address a patient’s condition before it ... now getting on board. , “You do the right thing, at the right time, at ... down, not up,” said Leonard M. Fromer, MD, FAAFP, from Group Practice Forum. “Even if ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 4, 2016 Research ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved significantly ... expected to be developed in coming years. Many cancer ... Cancer stem cell therapies are also expected to be ...
(Date:5/3/2016)... to further expand product development, strengthen its disease modeling capabilities and increase market presence. Photo - ... ... ... ... Sino-German High-Tech Fund (SGHF) is an ...
(Date:5/3/2016)... Ariz. , May 3, 2016  As a ... twice contracted rheumatic fever, which damaged his heart. He ... But by June 2013, Shepherd,s heart was giving ... from death. On June 20, 2013, the ... Total Artificial Heart (TAH-t). Like a heart transplant, the ...
Breaking Medicine Technology: